← All trials
NCT00209534
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 1, 2003
- Primary completion
- —
- Completion date
- Feb 1, 2004
- First posted
- —
- Last posted
- —
- Enrollment
- 200
- Arms / groups
- — / —
- Source
- AACT · pre-existing
Sponsors
- EisaiLead sponsor
- MDS PharmaCollaborator
- Bio Analytical Research CorporationCollaborator
- CaligorRx, Inc.Collaborator
- HHI Clinical ResearchCollaborator
- Theorem Clinical ResearchCollaborator
- EisaiStudy director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.